Literature DB >> 20586732

Cardiovascular risk factors in epilepsy patients taking levetiracetam, carbamazepine or lamotrigine.

S Svalheim1, G Luef, M Rauchenzauner, L Mørkrid, L Gjerstad, E Taubøll.   

Abstract

OBJECTIVES: The aim of the study was to investigate risk factors for cardiovascular disease in patients with epilepsy using the new antiepileptic drug levetiracetam (LEV), compared with patients taking carbamazepine (CBZ) or lamotrigine (LTG).
METHODS: Two hundred and twelve patients and 80 controls (age: 18-45 years) of both genders were included. The patients had been treated with either LEV (n = 52), CBZ (n = 87) or LTG (n = 73) monotherapy for at least 6 months. Total cholesterol (TC), low-density lipoprotein (LDL) and high-density lipoprotein (HDL) were measured. Smoking, drinking habits and physical activity were recorded and body mass index (BMI) was calculated.
RESULTS: Neither LEV nor LTG altered TC, LDL or HDL. Both men and women using CBZ had higher TC, HDL and LDL than controls. LDL/HDL and TC/HDL ratios were unchanged. Women on CBZ and LTG had a greater BMI when compared with the control group. Patients with epilepsy recorded less physical activity and lower alcohol use than the controls.
CONCLUSIONS: Neither LEV nor LTG affected blood lipid levels, while patients treated with CBZ have higher cholesterol, HDL and LDL than controls. The patients were less physically active, and women on CBZ and LTG had higher BMI.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20586732     DOI: 10.1111/j.1600-0404.2010.01372.x

Source DB:  PubMed          Journal:  Acta Neurol Scand Suppl        ISSN: 0065-1427


  4 in total

1.  Comparison of body composition in persons with epilepsy on conventional & new antiepileptic drugs.

Authors:  Sudhir Chandra Sarangi; Manjari Tripathi; Ashish Kumar Kakkar; Yogendra Kumar Gupta
Journal:  Indian J Med Res       Date:  2016-03       Impact factor: 2.375

2.  Assessment of atherosclerotic risk among patients with epilepsy on valproic acid, lamotrigine, and carbamazepine treatment.

Authors:  Nudrat A Zuberi; Mukhtiar Baig; Shazia Bano; Zehra Batool; Saeeda Haider; Tahira Perveen
Journal:  Neurosciences (Riyadh)       Date:  2017-04       Impact factor: 0.906

3.  Cardiac sodium channel inhibition by lamotrigine: In vitro characterization and clinical implications.

Authors:  Lindsey Ingleby-Talecki; Sven C van Dijkman; Sean P Oosterholt; Oscar Della Pasqua; Christina Winter; Marianne Cunnington; Linda Rebar; Sergio Forero-Schwanhaeuser; Vickas Patel; James A Cooper; Anthony Bahinski; Khuram W Chaudhary
Journal:  Clin Transl Sci       Date:  2022-05-31       Impact factor: 4.438

4.  Network-based approach to prediction and population-based validation of in silico drug repurposing.

Authors:  Feixiong Cheng; Rishi J Desai; Diane E Handy; Ruisheng Wang; Sebastian Schneeweiss; Albert-László Barabási; Joseph Loscalzo
Journal:  Nat Commun       Date:  2018-07-12       Impact factor: 14.919

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.